Satellos Bioscience Inc. Common Stock
MSLE
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.36M
Close$
$8.06
39.2% upside
Current Fair Value
39.2% upsideUndervalued by 39.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.36 Million |
|---|---|
| Enterprise Value | $-11,402,617.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-20.4 |
| Beta | 1.17 |
| Outstanding Shares | 18,435,110 |
Return
| Return on Equity | -40.01% |
|---|---|
| Return on Assets | -37.58% |
| Return on Invested Capital | -42.15% |
Valuation & Multiples
| P/E Ratio | -1.76 |
|---|---|
| PEG | -3.1 |
| Price to Sales | - |
| Price to Book Ratio | 1.93 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.38 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 54.48%▲ 54.48% |
|---|---|
| Total Invested | $42.79M |
| Investors Holding | 31▲ 31.00% |
ESG Score
No data
About Satellos Bioscience Inc. Common Stock
14 employees
CEO: Francis Gleeson Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based reg...